Search clinical trials for: ANX007

Total 65 results

Annexon, Inc.

Completed

Study of ANX007 in Participants With Primary Open-angle Glaucoma

Open Angle Glaucoma

United States
Annexon, Inc.

Completed

Single-dose Study of ANX007 in Participants With Primary Open-angle Glaucoma

Open-angle Glaucoma

United States
Janux Therapeutics

Recruiting

Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

Prostate Cancer | Metastatic Castration-resistant Prostate Cancer | Castration Resistant Prostatic Cancer

United States, Australia
Annexon, Inc.

Recruiting

Study of ANX005 in Adults With Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis

United States, Canada
Annexon, Inc.

Completed

An Open Label Study of ANX005 in Subjects With, or at Risk for, Manifest Huntington's Disease

Huntington Disease

United States
Annexon, Inc.

Active, not recruiting

A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Patients With Geographic Atrophy (ARCHER)

Geographic Atrophy

United States, Australia, New Zealand
Pfizer

Completed

Study to Assess Safety, Tolerability and Pharmacokinetics of APX001 Administered by Intravenous Infusion to Healthy Subjects

Fungal Infection

Netherlands
Kind Pharmaceuticals LLC

Not yet recruiting

A Study of Safety and Efficiency of AND017 in Patients With Transfusion Dependent and Non-transfusion Dependent β-thalassemia

β -Thalassemia
Annexon, Inc.
Nucleus Network Ltd

Completed

A Single and Multiple Ascending Dose Study of ANX009 in Normal Healthy Volunteers (NHV)

Safety and Tolerability in Healthy Volunteers

Australia
Adlai Nortye Biopharma Co., Ltd.

Recruiting

First in Human, Dose Escalation Study of AN4005

Advanced Solid Tumor | Advanced Lymphoma

United States, China
Pfizer

Completed

Safety, Pharmacokinetics, Bioavailability, Food Effect, Drug-Drug Interaction Study of APX001 Administered Orally

Fungal Infection

Netherlands
Annexon, Inc.

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ANX005 in Participants With Warm Autoimmune Hemolytic Anemia (wAIHA)

Warm Autoimmune Hemolytic Anemia (wAIHA)

United States
Annexon, Inc.

Terminated

Single Dose Study of ANX005 in Healthy Volunteers

Safety and Tolerability in Healthy Volunteers

Australia
Kind Pharmaceuticals LLC

Completed

A Dose-escalation Study of AND017 in Healthy Subjects

Healthy Volunteers

Australia
Santalis Pharmaceuticals, Inc.
ClinDatrix, Inc.; Fremantle Dermatology

Withdrawn

A Trial of a Botanical Drug Product Containing East Indian Sandalwood Oil (EISO) For Treatment of Atopic Dermatitis

Atopic Dermatitis
Kind Pharmaceuticals LLC

Not yet recruiting

A Study of AND017 in Cancer Related Anemic Patients Receiving Chemotherapy

Chemotherapy Induced Anemia
Janux Therapeutics

Recruiting

Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies

Renal Cell Carcinoma | Non-Small Cell Lung Cancer | Squamous Cell Carcinoma of the Head and Neck | Colorectal Carcinoma

United States
AiViva BioPharma, Inc.

Completed

Effect of Intravitreally Administered AIV007 in Subjects With nAMD

Neovascular Age-related Macular Degeneration

United States
Coegin Pharma AB
Bispebjerg Hospital; Studies&Me

Active, not recruiting

Phase I/IIa Trial to Evaluate AVX001 Gel in Doses of 1% or 3% Compared With Vehicle Over Four Weeks of Field-directed Treatment Period in Adult Subjects With AK (COAKS)

Actinic Keratoses

Denmark
Kind Pharmaceuticals LLC

Not yet recruiting

A Study of AND017 to Treat Cancer Related Anemia in Patients Not Receiving Chemotherapy

Cancer-Related Anemia
Annexon, Inc.

Recruiting

Efficacy and Safety of ANX005 in Subjects With Guillain-Barré Syndrome

Guillain-Barre Syndrome

Bangladesh, Philippines
Kind Pharmaceuticals LLC

Not yet recruiting

A Study of Efficacy and Safety of AND017 in Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes
AiViva BioPharma, Inc.

Recruiting

Effect of AIV007 by Periocular Administration in Subjects With nAMD or DME

Diabetic Macular Edema | Neovascular Age-related Macular Degeneration

United States
Kind Pharmaceuticals LLC

Completed

A Food-Effect Study of AND017 in Healthy Participants

Healthy Volunteers

China
Annexon, Inc.

Recruiting

Single Ascending Dose Study of ANX105

Healthy

Netherlands
Pfizer

Completed

An Open-label Study of APX001 for Treatment of Patients With Candidemia/Invasive Candidiasis Caused by Candida Auris (APEX)

Candidemia | Candida Infection | Invasive Candidiases

South Africa
Hoffmann-La Roche

Recruiting

A Study to Evaluate Single Subcutaneous Doses of NXT007 Among Injection Sites Abdomen, Upper Arm, and Thigh in Healthy Male Participants

Healthy Male Participants

New Zealand
Kind Pharmaceuticals LLC

Completed

A Study of AND017 to Treat Anemia in Non-dialysis-Dependent Chronic Kidney Disease (NDD-CKD) Patients

Renal Anemia

China, United States
Asana BioSciences

Completed

A Study of ASN007 in Patients With Advanced Solid Tumors

Cancer | Neoplasm Metastasis | Pancreatic Cancer | Metastatic Cancer | Metastatic Lung Cancer | Pancreas Adenocarcinoma | Metastatic Melanoma | Colon Cancer | Colonic Neoplasms | Pancreas Cancer | Non Small Cell Lung Cancer Metastatic | Neoplasm | Pancreas Neoplasm | Metastatic Pancreatic Cancer | Metastatic Colon Cancer and other conditions

United States
Pfizer

Terminated

Open-label Study of APX001 for Treatment of Patients With Invasive Mold Infections Caused by Aspergillus or Rare Molds (AEGIS)

Invasive Fungal Infections

Israel, Germany, United States, Belgium
Institut National de la Santé Et de la Recherche...
Rigshospitalet, Denmark

Unknown

Triheptanoin in Mc Ardle

Glycogen Storage Disease Type V
Rigshospitalet, Denmark
University of Texas Southwestern Medical Center; Groupe Hospitalier Pitie-Salpetriere and other collaborators

Completed

The Effect of Triheptanoin in Adults With McArdle Disease (Glycogen Storage Disease Type V)

Glycogen Storage Disease Type V

Denmark
Pfizer

Completed

A Study to Assess the Mass Balance Recovery and Metabolite Profile & Identification of [14C]-APX001 in Healthy Males

Fungal Infection

United Kingdom
Areeg El-Gharbawy
Ultragenyx Pharmaceutical Inc

Completed

Anaplerotic Therapy Using Triheptanoin for Patients With Glycogen Storage Disease Type I

Glycogen Storage Disease Type I

United States
University of Liege

Unknown

A Pilot Trial of Triheptanoin for the Preventive Treatment of Migraine (TRIMI)

Migraine
Ultragenyx Pharmaceutical Inc

Terminated

Study to Assess the Long Term Safety and Efficacy of UX007 in Participants With Glucose Type 1 Deficiency Syndrome (Glut1 DS)

Glucose Transporter Type 1 Deficiency Syndrome

United States, Spain, Denmark, United Kingdom, Australia
Ultragenyx Pharmaceutical Inc

Terminated

Crossover Study to Assess the Efficacy and Safety of UX007 in the Treatment of Movement Disorders Associated With Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)

Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)

United States, Spain, France, Germany, Italy, United Kingdom
Jerry Vockley, MD, PhD
Ultragenyx Pharmaceutical Inc

No longer available

Treatment With UX007 for a Single Patient With GLUT1 Deficiency Syndrome

Glucose Transporter 1 Deficiency Syndrome

United States
Santalis Pharmaceuticals, Inc.
Derm Research, PLLC; ClinDatrix, Inc.; Texas Dermatology and Laser Specialists; Clinical Trials of Texas, Inc... and other collaborators

Completed

A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) For Treatment of Atopic Dermatitis

Eczema | Atopic Dermatitis

United States
Ultragenyx Pharmaceutical Inc

Completed

A Study of UX007 (Triheptanoin) in Participants With Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD)

Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) | Very Long Chain Acyl-CoA Dehydrogenase (VLCAD) Deficiency | Trifunctional Protein (TFP) Deficiency | Carnitine Palmitoyltransferase (CPT II) Deficiency | Longchain 3-hydroxy-acyl-CoA Dehydrogenase (LCHAD) Deficiency

United States, United Kingdom
Hoffmann-La Roche

Recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A

Hemophilia A

Spain, Canada, United States, New Zealand, Italy, Poland
Pfizer

Completed

An Efficacy and Safety Study of APX001 in Non-Neutropenic Patients With Candidemia

Candidemia

Germany, United States, Israel, Spain, Belgium
Kind Pharmaceuticals LLC

Active, not recruiting

A Study of AND017 to Treat Anemia in Chronic Kidney Disease Patients on Dialysis

Renal Anemia

United States
Pfizer

Completed

A Bioequivalence Study of APX001 High-load and Low-load Tablets

Invasive Fungal Infections

United States
Abbott Nutrition

Not yet recruiting

Benefits of Nutritional Ingredients for Type 2 Diabetes

Diabetes type2
Tigris Pharmaceuticals

Completed

Safety and Efficacy of A-007 Topical Gel in the Treatment of High-Grade Squamous Intraepithelial Lesions (HSIL) of the Cervix

Cervical Intraepithelial Neoplasia | Uterine Cervical Dysplasia

United States
Annexon, Inc.

Recruiting

A Study of ANX009 in Adult Participants With Lupus Nephritis

Lupus Nephritis

Philippines, Taiwan
Ultragenyx Pharmaceutical Inc

Available

Expanded Access to Triheptanoin

Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)
Irina A Anselm

No longer available

Triheptanoin (UX007) to Treat Citrate Transporter Deficiency

Citrate Transporter Deficiency | SLC13A5 Gene Mutation

United States
Ultragenyx Pharmaceutical Inc

Completed

Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Extension Study for Subjects Previously Enrolled in Triheptanoin Studies

Carnitine Palmitoyltransferase (CPT I or CPT II) Deficiency | Very Long Chain Acyl-CoA Dehydrogenase (VLCAD) Deficiency | Long-chain 3-hydroxy-acyl-CoA Dehydrogenase (LCHAD) Deficiency | Trifunctional Protein (TFP) Deficiency | Carnitine-acylcarnitine Translocase (CACT) Deficiency

United States, United Kingdom

Search clinical trials for: ANX007

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Myanmar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations